open access

Vol 9, Supp. A (2018)
Case report
Get Citation

Successful nilotinib treatment in a patient with chronic myelogenous leukemia after failure of treatment with two tyrosine kinase inhibitors due to intolerance and resistance

Edyta Paczkowska1
DOI: 10.5603/Hem.2018.0009
Affiliations
  1. Klinika Hematologii z Oddziałem Transplantacji Szpiku, Samodzielny Publiczny Szpital Kliniczny nr 1 PUM im. prof. Tadeusza Sokołowskiego, zpital Kliniczny nr 1 PUM im. prof. Tadeusza Sokołowskiego w Szczecinie, ul. Unii Lubelskiej 1, 71–252 Szczecin, 71–252 Szczecin, Poland

open access

Vol 9, Supp. A (2018)
CASE REPORTS

Abstract

Treatment with tyrosine kinase inhibitors (TKI) produces good results in patients with chronic
myelogenous leukemia (CML). However, some patients need to change the therapy due to intolerance
or resistance to TKI applied. In these situations, the possibility of 2nd generation TKI administration
allows to achieve deep molecular response (DMR) and long survival of patients. In this
paper, a case of adult patient with CML who experienced hepatic toxicity of imatinib and failure
of dasatinib treatment due to resistance is presented. Subsequently, the treatment with nilotinib
resulted in a long-term DMR.

Abstract

Treatment with tyrosine kinase inhibitors (TKI) produces good results in patients with chronic
myelogenous leukemia (CML). However, some patients need to change the therapy due to intolerance
or resistance to TKI applied. In these situations, the possibility of 2nd generation TKI administration
allows to achieve deep molecular response (DMR) and long survival of patients. In this
paper, a case of adult patient with CML who experienced hepatic toxicity of imatinib and failure
of dasatinib treatment due to resistance is presented. Subsequently, the treatment with nilotinib
resulted in a long-term DMR.

Get Citation

Keywords

chronic myelogenous leukemia, tyrosine kinases inhibitors, intolerance, resistance

About this article
Title

Successful nilotinib treatment in a patient with chronic myelogenous leukemia after failure of treatment with two tyrosine kinase inhibitors due to intolerance and resistance

Journal

Hematology in Clinical Practice

Issue

Vol 9, Supp. A (2018)

Article type

Case report

Pages

4-8

Page views

250

Article views/downloads

311

DOI

10.5603/Hem.2018.0009

Keywords

chronic myelogenous leukemia
tyrosine kinases inhibitors
intolerance
resistance

Authors

Edyta Paczkowska

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.